Top

Published in:

01-04-2019 | Insulins | Article

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes

Authors: Ming-Feng Xia, Huan-Dong Lin, Ling-Yan Chen, Li Wu, Hui Ma, Qian Li, Qiqige Aleteng, Yu Hu, Wan-Yuan He, Jian Gao, Hua Bian, Xiao-Ying Li, Xin Gao

Published in: Diabetologia | Issue 4/2019

Abstract

Aims/hypothesis

The rs738409 C>G variant of the patatin-like phospholipase domain containing 3 gene (PNPLA3) increases the risk of non-alcoholic fatty liver disease (NAFLD) with no predisposition for insulin resistance. In this study, we aimed to investigate the influence of PNPLA3 polymorphisms on liver fat content (LFC) and glucose metabolic variables, and the associations between these, during the natural course of body weight changes in a Chinese adult cohort.

Methods

The LFC, measured using a quantitative ultrasound method, was prospectively monitored in 2189 middle-aged and elderly adults from the Shanghai Changfeng Study, together with changes in body weight and metabolic variables. General linear models were used to detect interactive effects between the PNPLA3 rs738409 genotype and 4 year changes in body weight on liver steatosis and glucose metabolism.

Results

The PNPLA3 homozygous GG genotype dissociated the changes in the LFC and OGTT 2 h post-load blood glucose (PBG) in relation to 4 year changes in body weight. PNPLA3 GG genotype carriers showed greater increases in the LFC and serum alanine aminotransferase (ALT) but lower PBG elevation and incident diabetes than PNPLA3 wild-type (CC) genotype carriers exhibiting the same degree of body weight increase. The interactions between the PNPLA3 genotype and changes in body weight on the LFC (false discovery rate [FDR]-adjusted p_interaction = 0.044) and ALT (FDR-adjusted p_interaction = 0.044) were significant. Subgroup analyses showed that the effect of the PNPLA3 GG genotype on changes in the LFC and PBG was only observed in metabolically unhealthy participants with insulin resistance or abdominal obesity.

Conclusions/interpretation

The PNPLA3 GG genotype interacted with changes in body weight to aggravate liver steatosis but reduced the risk of incident type 2 diabetes in metabolically unhealthy participants.

Available only for authorised users

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of non-alcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431 CrossRefPubMed

Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363(14):1341–1350. https://doi.org/10.1056/NEJMra0912063 CrossRefPubMed

Wang AY, Dhaliwal J, Mouzaki M (2018) Lean non-alcoholic fatty liver disease. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.08.008

Anstee QM, Day CP (2015) The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 35(3):270–290CrossRef

Yki-Järvinen H, Luukkonen PK (2015) Heterogeneity of non-alcoholic fatty liver disease. Liver Int 35(12):2498–2500. https://doi.org/10.1111/liv.12970 CrossRefPubMed

Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461–1465. https://doi.org/10.1038/ng.257 CrossRefPubMedPubMedCentral

Santoro N, Kursawe R, D’Adamo E et al (2010) A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52(4):1281–1290. https://doi.org/10.1002/hep.23832 CrossRefPubMedPubMedCentral

Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 50(10):2111–2116. https://doi.org/10.1194/jlr.P900013-JLR200 CrossRefPubMedPubMedCentral

Trépo E, Nahon P, Bontempi G et al (2014) Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 59(6):2170–2177. https://doi.org/10.1002/hep.26767 CrossRefPubMed

10.

Petäjä EM, Yki-Järvinen H (2016) Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD—a systematic review. Int J Mol Sci 17(5):633. https://doi.org/10.3390/ijms17050633 CrossRefPubMedCentral

11.

Speliotes EK, Butler JL, Palmer CD et al (2010) PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52(3):904–912. https://doi.org/10.1002/hep.23768 CrossRefPubMedPubMedCentral

12.

Meffert PJ, Repp KD, Völzke H et al (2017) The PNPLA3 SNP rs738409: G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort. J Hepatol 68:858–860CrossRef

13.

Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC (2017) Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49(6):842–847. https://doi.org/10.1038/ng.3855 CrossRefPubMedPubMedCentral

14.

Xia MF, Ling Y, Bian H et al (2016) I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther 43(5):631–642. https://doi.org/10.1111/apt.13521 CrossRefPubMed

15.

Romeo S, Sentinelli F, Dash S et al (2010) Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes 34(1):190–194. https://doi.org/10.1038/ijo.2009.216 CrossRef

16.

Sanyal AJ, American Gastroenterological Association (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123(5):1705–1725. https://doi.org/10.1053/gast.2002.36572 CrossRefPubMed

17.

Hu FB (ed) (2008) Obesity epidemiology. Oxford University Press, New York

18.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59(6):1121–1140

19.

American Diabetes Association (2018) Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S51–S54. https://doi.org/10.2337/dc18-S005 CrossRef

20.

Gao X, Hofman A, Hu Y et al (2010) The Shanghai Changfeng Study: a community-based prospective cohort study of chronic diseases among middle-aged and elderly: objectives and design. Eur J Epidemiol 25(12):885–893. https://doi.org/10.1007/s10654-010-9525-6 CrossRefPubMed

21.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502

22.

Xia MF, Yan HM, He WY et al (2012) Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 20(2):444–452. https://doi.org/10.1038/oby.2011.302 CrossRef

23.

WHO (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva

24.

Stefan N, Häring HU, Hu FB, Schulze MB (2013) Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1(2):152–162. https://doi.org/10.1016/S2213-8587(13)70062-7 CrossRefPubMed

25.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57:289–300

26.

Du S, Wang C, Jiang W et al (2016) The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood. Diabetes Res Clin Pract 116:183–191. https://doi.org/10.1016/j.diabres.2016.04.047 CrossRefPubMed

27.

Zheng Y, Manson JE, Yuan C et al (2017) Associations of weight gain from early to middle adulthood with major health outcomes later in life. JAMA 318(3):255–269. https://doi.org/10.1001/jama.2017.7092 CrossRefPubMedPubMedCentral

28.

Xia MF, Lin HD, Chen LY et al (2018) Association of visceral adiposity and its longitudinal increase with the risk of diabetes in Chinese adults: a prospective cohort study. Diabetes Metab Res Rev 34(7):e3048. https://doi.org/10.1002/dmrr.3048 CrossRefPubMed

29.

Sevastianova K, Kotronen A, Gastaldelli A et al (2011) Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94(1):104–111. https://doi.org/10.3945/ajcn.111.012369 CrossRefPubMed

30.

Shen J, Wong GL, Chan HL et al (2015) PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 30(1):139–146. https://doi.org/10.1111/jgh.12656 CrossRefPubMed

31.

Krawczyk M, Jiménez-Agüero R, Alustiza JM et al (2016) PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 12(10):1838–1846. https://doi.org/10.1016/j.soard.2016.06.004 CrossRefPubMed

32.

Sevastianova K, Santos A, Kotronen A et al (2012) Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 96(4):727–734. https://doi.org/10.3945/ajcn.112.038695 CrossRefPubMed

33.

Koot BG, van der Baan-Slootweg OH, Vinke S et al (2016) Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J Obes 40(1):51–57. https://doi.org/10.1038/ijo.2015.175 CrossRef

34.

Scorletti E, West AL, Bhatia L et al (2015) Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 63(6):1476–1483. https://doi.org/10.1016/j.jhep.2015.07.036 CrossRefPubMed

35.

Huang Y, He S, Li JZ et al (2010) A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 107(17):7892–7897. https://doi.org/10.1073/pnas.1003585107 CrossRefPubMedPubMedCentral

36.

Smagris E, BasuRay S, Li J et al (2015) Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61(1):108–118. https://doi.org/10.1002/hep.27242 CrossRefPubMed

37.

Kantartzis K, Peter A, Machicao F et al (2009) Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58(11):2616–2623. https://doi.org/10.2337/db09-0279 CrossRefPubMedPubMedCentral

38.

Park JH, Cho B, Kwon H et al (2015) I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int 35(12):2537–2546. https://doi.org/10.1111/liv.12909 CrossRefPubMed

39.

Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M (2008) Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol 159(5):577–583. https://doi.org/10.1530/EJE-08-0426 CrossRefPubMed

40.

Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53(6):1549–1555. https://doi.org/10.2337/diabetes.53.6.1549 CrossRefPubMed

41.

Luukkonen PK, Zhou Y, Sädevirta S et al (2016) Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64(5):1167–1175. https://doi.org/10.1016/j.jhep.2016.01.002 CrossRefPubMed

42.

Mitsche MA, Hobbs HH, Cohen JC (2018) Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 293(18):6958–6968. https://doi.org/10.1074/jbc.RA118.002333 CrossRefPubMedPubMedCentral

43.

Xia M, Bian H, Yan H et al (2015) Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases. Obesity 23(9):1929–1937. https://doi.org/10.1002/oby.21182 CrossRefPubMed

Title: The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes
Authors: Ming-Feng Xia
Huan-Dong Lin
Ling-Yan Chen
Li Wu
Hui Ma
Qian Li
Qiqige Aleteng
Yu Hu
Wan-Yuan He
Jian Gao
Hua Bian
Xiao-Ying Li
Xin Gao
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Insulins
Type 2 Diabetes
Published in: Diabetologia / Issue 4/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4805-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 4/2019

Correction to: The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes

Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study

Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex

Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage